Global Age Related Macular Degeneration Market Expected to Surpass $16.2 Billion by 2033 The global age-related macular degeneration market is projected to reach $16.2 billion by 2033, driven by rising cases and aging populations.

Global Age Related Macular Degeneration Market Expected to Surpass $16.2 Billion by 2033 #None #Wet_AMD #Aflibercept #Age_Related_Macular_Degeneration

REGENXBIO Completes Enrollment in Landmark Trials for Vision Loss Treatment REGENXBIO Inc. has wrapped up participant enrollment in pivotal studies for its gene therapy aimed at treating wet AMD. This marks a significant step in fighting vision loss globally.

REGENXBIO Completes Enrollment in Landmark Trials for Vision Loss Treatment #United_States #Wet_AMD #Rockville #REGENXBIO #surabgene

Avirmax Biopharma Reaches Key Milestone with ABI-110 Clinical Trial Enrollment Completion Avirmax Biopharma has successfully completed the first cohort of patient enrollment for its ABI-110 clinical trial targeting Wet AMD and PCV, marking a significant milestone.

Avirmax Biopharma Reaches Key Milestone with ABI-110 Clinical Trial Enrollment Completion #USA #Avirmax_Biopharma #Wet_AMD #ABI-110 #Hayward

Avirmax Biopharma Launches Groundbreaking Gene Therapy Trial for Wet AMD Avirmax Biopharma has commenced the Phase I/IIa trial of ABI-110, a pioneering gene therapy targeting Wet Age-related Macular Degeneration and PCV.

Avirmax Biopharma Launches Groundbreaking Gene Therapy Trial for Wet AMD #USA #Avirmax_Biopharma #Wet_AMD #ABI-110 #Hayward